Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
J Dairy Sci ; 98(11): 7560-72, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26364106

ABSTRACT

The guarantee of the origin and quality of raw material is essential for the protection and valorization of Campana buffalo mozzarella cheese. The risk of utilization of semifinished products and stored milk in substitution for fresh milk is increasing, due to the continuous desire to reduce production costs. A proteomics approach and electrophoresis survey of retail mozzarella cheeses indicated different rates of proteolysis in the production of dairy industries. The use of fresh milk and correct cheesemaking protocol yielded only γ-caseins, which are derived from ß-casein by plasmin, and para-κ-casein, which is derived from κ-casein by chymosin. The detection of abnormal hydrolysis resulting in ß- and αS1-casein fragments, identified by mass spectrometry, indicates the use of stored milk or stored and pressed curd, or the reuse of unsold mozzarella cheese, to produce mozzarella. The formation of γ-caseins and other fragments during a long storage of raw materials at room or refrigeration temperature was ascribed to plasmin (endogenous milk enzyme), whereas formation of αS1-casein fragments, mainly αS1-I(6P)- and αS1-I(7P)-casein during the storage of curd was ascribed to the action of chymosin (exogenous enzyme) from rennet. Sodium dodecyl sulfate-PAGE and alkaline urea-PAGE permitted us to evaluate the freshness of the raw materials used in the manufacturing of buffalo mozzarella cheese and to reveal possible inappropriate preservation.


Subject(s)
Cheese/analysis , Proteolysis , Proteomics , Animals , Buffaloes , Caseins/metabolism , Chromatography, Liquid , Chymosin/metabolism , Electrophoresis, Polyacrylamide Gel , Fibrinolysin/metabolism , Food Handling , Food Storage , Milk/chemistry , Principal Component Analysis , Tandem Mass Spectrometry
2.
Clin Biochem ; 44(13): 1160-1162, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21704612

ABSTRACT

OBJECTIVE: To evaluate Liaison Diasorin's automated ACTH assay. DESIGN: We investigated the limit of quantification (LOQ) and simulated the usage of the analyzer using our ACTH results database. RESULTS: The LOQ was close to the cut-off determining Cushing's syndrome ACTH dependency. 25% concentrations of normal subjects were lower than the LOQ. Although biased, the results were concordant with those of an IRMA assay. CONCLUSION: This assay is not sensitive enough to diagnose ACTH-independent Cushing's syndrome.


Subject(s)
Adrenal Gland Diseases/diagnosis , Adrenocorticotropic Hormone/analysis , Diagnostic Techniques and Procedures/standards , Pituitary Diseases/diagnosis , Cushing Syndrome/diagnosis , Humans , Limit of Detection , Sensitivity and Specificity
3.
J Endocrinol Invest ; 34(6): 427-30, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21508661

ABSTRACT

BACKGROUND: Erythropoietin (EPO) is an oxygenregulated hormone promoting the differentiation of erythroid progenitor cells. Apart fromhypoxia, few data is available about release by secretagogues including hormones. AIM: To investigate EPO serum concentration in subjects with endocrine diseases. MATERIAL AND METHODS: A retrospective study evaluating serumEPO concentrations in serumleftovers fromsubjects with various endocrine disorders. RESULTS: EPO is not noticeably influenced by thyroid hormone or cortisol concentrations and the relationship with hemoglobin concentration is preserved. In acromegalic patients, the latter is lost but EPO is neither statistically influenced by GH/IGF-I. This may reflect a dual action of GH and/or IGF-I on erythroid progenitors proliferation as well as on EPO synthesis. CONCLUSION: EPO is not noticeably modified by endocrine disorders although GH and or IGF-I may alter EPO relationship with blood hemoglobin concentration.


Subject(s)
Biomarkers/blood , Endocrine System Diseases/blood , Erythropoietin/blood , Adolescent , Adult , Aged , Aged, 80 and over , Endocrine System Diseases/diagnosis , Female , Follow-Up Studies , Hemoglobins/analysis , Hormones/blood , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , Young Adult
4.
Ann Endocrinol (Paris) ; 70(4): 211-7, 2009 Sep.
Article in French | MEDLINE | ID: mdl-19457469

ABSTRACT

OBJECTIVES: To compare clinical, vascular and metabolic parameters before and after surgery in patients with subclinical cortisol secreting incidentalomas. PATIENTS AND METHODS: Eight patients were investigated before and 12 months after removal of the mass on hemodynamic (blood pressure by MAPA procedure), anthropometric (body weight, body mass index), and metabolic parameters (glucose level, HbA(1c)). RESULTS: In the whole group, 75% of patients displayed decrease in blood pressure (cessation of at least one hypotensive medication) and 33% of them were definitely cured of hypertension. Seventy-one percent of patients lost body weight and 37.5% lost more than 5%. In the whole group of patients, glucose level decreased by 1.1% and medical treatment was discontinuated in two of three diabetic patients. CONCLUSION: Subclinical cortisol secreting adrenal incidentalomas are associated with cardiovascular risk factors that may be corrected after removal of the mass. Therefore, surgery may be an appropriate choice in patients with subclinical Cushing's syndrome to improve hypertension, body weight and impaired glucose level. Controlled studies comparing surgical treatment to a medical follow-up including optimal cardiovascular risk factors treatment are needed to define the usefulness of surgery in hypertensive patients with subclinical cortisol secreting incidentalomas.


Subject(s)
Adrenal Gland Neoplasms/surgery , Blood Glucose/metabolism , Blood Pressure/physiology , Hydrocortisone/blood , Adrenal Gland Neoplasms/complications , Adrenal Gland Neoplasms/metabolism , Adrenal Gland Neoplasms/physiopathology , Adrenocorticotropic Hormone/blood , Aged , Body Mass Index , Cardiovascular Diseases/epidemiology , Cushing Syndrome/complications , Cushing Syndrome/surgery , Female , Humans , Hydrocortisone/metabolism , Male , Middle Aged
6.
J Mol Endocrinol ; 34(3): 849-58, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15956352

ABSTRACT

In vivo assessment of the cellular impact of thyroid hormones on target tissues might be of help for physiological studies and to evaluate the consequences of various diseases of the thyroid gland in humans. Given the tenuous relationship between retinoid and tri-iodothyronine (T3) status and that retinoids have also intracellular roles, the aim of this study was to determine the effect of hypothyroidism on the expression of T3 nuclear receptors (TR) and retinoic acid nuclear receptors (RAR, RXR) in human peripheral blood mononuclear cells (PBMC). Using real time RT-PCR, we quantified the relative amount of mRNA of the thyroid (TR alpha and TR beta) and retinoid (RAR alpha, RAR gamma, and RXR alpha) nuclear receptors in PBMC of euthyroid (n = 22) compared with hypothyroid (n = 22) subjects. Classical plasma parameters (free T3 (FT3), free thyroxine (T4) (FT4), thyroid-stimulating hormone (TSH), retinol (ROH), retinol-binding protein (RBP) and transthyretin (TTR)) were also measured. In hypothyroid subjects, the concentration of TSH was elevated, and dramatically low T3 and T4 concentrations were associated with a decrease in the expression of TR beta. Expression of RAR alpha and RAR gamma significantly decreased in hypothyroid versus control subjects, while an increased concentration of ROH was emphasised by hypothyroidism. These results first indicated that primary hypothyroidism induces hypoactivation of the retinoid nuclear pathway in PBMC, which was not predicted by the plasma ROH level. Further investigations will be necessary to evaluate these parameters in very small changes in thyroid hormone production such as mild (subclinical) hypothyroidism.


Subject(s)
Hypothyroidism/blood , Monocytes/metabolism , RNA, Messenger/genetics , Retinoid X Receptor alpha/genetics , Retinoid X Receptor gamma/genetics , Base Sequence , DNA Primers , Female , Humans , Hypothyroidism/genetics , Male , Receptors, Thyroid Hormone/genetics , Reverse Transcriptase Polymerase Chain Reaction
7.
Clin Endocrinol (Oxf) ; 55(4): 447-54, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11678826

ABSTRACT

OBJECTIVES: Obesity with abdominal body fat distribution (A-BFD) and hypothalamic-pituitary-adrenal (HPA) axis activity are somehow linked, but the exact interactions still need clarification. Obese subjects display normal circulating plasma cortisol concentrations with normal circadian rhythms. However, when the HPA axis is pharmacologically challenged, body fat distribution matters and then A-BFD obese women differ from those with subcutaneous body fat distribution (P-BFD). We hypothesized that lower dose provocative and suppressive tests than those used to diagnose hypercortisolism of tumour origin or adrenal insufficiency would shed some light on the characteristics of the HPA axis activity in relation with body fat distribution. PATIENTS AND METHODS: Fifty premenopausal obese women were grouped according to their body fat mass distribution. Their plasma cortisol responses to (i) two low doses of dexamethasone (0.25 and 0.5 mg) with (ii) low dose of the ACTH analogue tetracosactrin (1 microg) were assessed. Salivary cortisol was also determined during the ACTH test. RESULTS: A-BFD differed from P-BFD women in terms of HPA axis responsiveness. They had comparatively: (i) increased nocturnal cortisol excretion (9.38 +/- 2.2 vs. 6.82 +/- 0.91 nmol/micromol creatinine, A-BFD vs. P-BFD, respectively, P = 0.03); (ii) increased salivary cortisol response to ACTH stimulation (1 microg) [salivary cortisol peak: 33.4 (14.1-129) vs. 28.5 (13.2-42.8) nmol/l; salivary AUC: 825 (235-44738) vs. 537 (69-1420) nmol/min/l; A-BFD vs. P-BFD, P = 0.04 for both]; and (iii) increased pituitary sensitivity to dexamethasone testing [postdexamethasone (0.25 mg) plasma cortisol levels: 163 (26-472) vs. 318 (26-652) nmol/l and postdexamethasone (0.5 mg) plasma cortisol levels: 26 (26-79) vs. 33 (26-402) nmol/l; A-BFD vs. P-BFD, P = 0.01 for both). CONCLUSIONS: These data demonstrate differences in the HPA axis activity and sensitivity to glucocorticoids between obese women differing in their body fat distribution, with both enhanced negative and positive feedback in those with abdominal obesity. Several mechanisms may explain these differences: central vs. peripheral hypotheses. Thus, abdominal obesity does not appear to be linked solely to one pathophysiological hypothesis.


Subject(s)
Body Constitution/physiology , Dexamethasone , Glucocorticoids , Hypothalamo-Hypophyseal System/physiopathology , Obesity/physiopathology , Pituitary-Adrenal System/physiopathology , Adolescent , Adult , Analysis of Variance , Cosyntropin , Dexamethasone/blood , Female , Humans , Hydrocortisone/analysis , Hydrocortisone/blood , Middle Aged , Obesity/metabolism , Saliva/chemistry
9.
J Hypertens ; 19(6): 1029-35, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11403350

ABSTRACT

OBJECTIVE: To audit the performances of the analytes used in the diagnosis of pheochromocytoma and to present a graphical guideline to help the diagnosis. DESIGN: A 5 year retrospective study. SETTINGS: Laboratory and departments of a university hospital. PARTICIPANTS: In-patients, suspected of bearing a pheochromocytoma, were investigated for urinary metanephrines and catecholamines (photometric method) and vanillylmandelic acid, fractionated catecholamines and metanephrines [high pressure liquid chromatography (HPLC) coupled to electrochemical detection (ED)] urinary excretion. MAIN OUTCOME: Patients with a pheochromocytoma (24 out of 2003 patients) were diagnosed by the combination of normetanephrine and metanephrine determination. RESULTS: All analytes but dopamine were significantly elevated in patients with a pheochromocytoma. The area under the receiver operating characteristics (ROC) curves were the highest for total metanephrines, normetanephrine and metanephrine determinations. Because of analytical interferences in the metanephrines determination, the normetanephrine and metanephrine performed better. It is noteworthy that all pheochromocytomas had either normetanephrine or metanephrine levels above their respective optimal threshold (sensitivity 100%). The best optimal threshold performance was reached by the mean of three daily samples. Total or fractionated catecholamines or vanillylmandelic acid were less accurate tools. CONCLUSION: Amongst urinary tests, the combined use of HPLC/ED determination of normetanephrine and metanephrine seems the most effective screening strategy for the diagnosis of pheochromocytoma. The older total metanephrine photometric assay is grieved by analytical interferences.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Adrenal Gland Neoplasms/urine , Metanephrine/urine , Normetanephrine/urine , Pheochromocytoma/diagnosis , Pheochromocytoma/urine , Adolescent , Adult , Aged , Catecholamines/urine , Chromatography, High Pressure Liquid , Electrochemistry , Female , Humans , Male , Middle Aged , Predictive Value of Tests , ROC Curve , Retrospective Studies , Vanilmandelic Acid/urine
10.
Diabet Med ; 17(6): 484-6, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10975220

ABSTRACT

AIMS: Atypical anti-psychotic drugs (APDs) are widely used in psychotic disorders refractory to conventional neuroleptic agents. RESULTS: Three cases of new-onset diabetes are reported in Caucasian men who were on clozapine (one) or olanzapine (two) for 3-6 months. They had a distinct presentation: weight loss, ketosis (one ketoacidosis), severe hyperglycaemia requiring insulin therapy, and relative insulin deficiency as reflected by glucagon stimulatory tests. In all cases, insulin was stopped within 1 month after the APD was discontinued. CONCLUSIONS: Novel APDs not only induce diabetes as a result of weight gain in predisposed patients, but can also lead to a reversible state of insulin deficiency, and sometimes ketoacidosis.


Subject(s)
Antipsychotic Agents/adverse effects , Diabetes Mellitus/chemically induced , Pirenzepine/analogs & derivatives , Psychotic Disorders/drug therapy , Adult , Benzodiazepines , Clozapine/adverse effects , Depressive Disorder/drug therapy , Diabetes Mellitus/diagnosis , Diabetes Mellitus/drug therapy , Glyburide/therapeutic use , Humans , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Male , Middle Aged , Olanzapine , Pirenzepine/adverse effects , Schizophrenia/drug therapy
11.
Diabetes Metab ; 25(4): 321-8, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10566121

ABSTRACT

Although insulin is a well-known cause of body weight gain, it is not clear whether it is due to the accumulation of fat or lean mass. We performed a 3 months Body-Impedance Analysis follow-up in 72 diabetic patients in a wide range of insulin indications: insulin introduction in young inaugural type 1 diabetics (n = 12), late-onset type 1 (n = 12), type 2 affected by intercurrent diseases (n = 12) or microangiopathic complications (n = 12), type 2 with failure of oral antidiabetic agents (n = 12), and insulin withdrawal in type 2 (n = 12). In type 1 patients, insulin led to the most important weight gain, but it was fat-free, with a major benefit on HbA1C. Type 2 patients affected by intercurrent diseases or microangiopathic complications had a mild, also fat-free weight gain, with a clear benefit on HbA1C. In type 2 patients with failure of oral agents, HbA1C declined less, weight gain was intermedia, but predominantly fat, mirrored by a predominant fat loss in type 2 patients whose insulin was stopped (without significant change in HbA1C). Both fat and lean mass contributed to insulin-induced body weight gain, but a significant negative relationship existed between their respective evolution in our patients (r = -0.23, p < 0.05 by linear regression analysis between delta fat mass and delta lean mass). Insulin-induced body weight gain is not univocal: insulin restaures or protects lean mass in its less controversial indications, whereas it leads to fat accumulation in type 2 patients with isolated failure of oral agents.


Subject(s)
Body Composition/drug effects , Hypoglycemic Agents/adverse effects , Insulin/adverse effects , Weight Gain/drug effects , Adult , Aged , Diabetes Mellitus, Type 2/drug therapy , Diabetic Angiopathies/drug therapy , Female , Humans , Male , Middle Aged , Regression Analysis , Sex Characteristics , Substance Withdrawal Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL
...